Fund Performance - The Summers Value Fund LP achieved a net return of 20.4% in Q3 2025, outperforming the Russell 2000 Index ETF (12.4%) and the Russell 2000 Value Index ETF (12.5%) [2] - Year-to-date, the Fund is up 4.9%, lagging behind the IWM (10.3%) and IWN (8.9%) [2] - Since inception, the Fund has delivered a 12.2% annualized net return compared to 6.8% for IWM and 6.1% for IWN [2][3] Healthcare Sector Overview - The healthcare sector has faced challenges leading to underperformance against broader indexes, influenced by regulatory uncertainty from new FDA leadership and budget pressures at federal agencies [4] - Investors withdrew approximately $13 billion from healthcare funds in 2025, indicating a record annual outflow, while large-cap stocks saw $224 billion in inflows [5] - Despite negative sentiment, the healthcare sector is viewed as defensive and growing, with potential for disciplined investors to find opportunities [5][6] Investment Opportunities - The Fund has increased exposure to biopharma stocks, anticipating outperformance due to an innovation cycle and potential acquisitions by large-cap companies [6] - Notable contributors to the Fund's performance in Q3 included Zimvie (124% acquisition premium), Liquidia (strong sales of Yutrepia), and Consensus Cloud Solutions (return to positive revenue growth) [7] - The Fund initiated a position in uniQure following promising Phase 3 results for its gene therapy drug, which showed a 75% reduction in disease progression [9] Position Updates - Journey Medical, with a market cap of $175 million, launched Emrosi for rosacea treatment, with annualized sales approaching $30 million and potential peak sales exceeding $100 million [12] - Ligand Pharmaceuticals, valued at $3.7 billion, operates as a royalty aggregator and is expected to see strong performance from its drugs Ohtuvaryre and Filspari, with blockbuster potential [13][14] - The Fund's top five holdings include Electromed, Consensus Cloud Solutions, Liquidia, Spok Holdings, and Ligand Pharmaceuticals, with a significant allocation to pharmaceutical and biotechnology stocks [10]

Market Overview - U.S. equities saw significant gains in Q3, driven by the Federal Reserve's first rate cut of the year, strong corporate earnings growth, and increased market participation [2] - Investor enthusiasm for artificial intelligence contributed to substantial gains in technology stocks, particularly among the "Magnificent Seven" [2] - Small-cap stocks outperformed as capital shifted into undervalued market segments, despite ongoing concerns about tariffs, inflation, and labor market softness [2] Company Highlights - Resideo Technologies, Inc. (REZI) was the top contributor in Q3, with organic revenue, EBITDA, and adjusted EPS exceeding expectations, and a positive outlook supported by demand for smart home solutions [3] - Barrick Mining Corporation (B) experienced a rise in shares due to strong financial results and rising gold prices, alongside a strategic divestiture of its Hemlo Gold Mine for $1.09 billion [4] - ZimVie, Inc. (ZIMV) advanced following an announcement of its acquisition by ARCHIMED, expected to close by year-end [5] - Mosaic Co. (MOS) was the biggest detractor from performance due to an earnings miss, with pressures from lower volumes and rising production costs, although phosphate markets are expected to remain tight through 2025 [6] - Prestige Consumer Healthcare Inc. (PBH) declined after mixed earnings results and a downward revision to guidance, but plans to strengthen supply through an acquisition of Pillar5 [7] - Schlumberger Limited (SLB) traded lower due to a challenging macroeconomic environment, with pressures from OPEC+ supply increases and geopolitical uncertainty impacting oil prices [8] New Positions and Exits - New positions included Arthur J. Gallagher & Co. (AJG), which faced pressure due to a delay in closing its $13.4 billion acquisition of AssuredPartners, but is expected to benefit from stronger synergies [10] - Fiserv, Inc. (FI) was also purchased, seen as a leading provider of payment processing and financial services technology, with a recent stock pullback providing an attractive entry point [11] - Exited positions included ZimVie, Inc., Core Laboratories, Inc. (CLB), and Bio-Rad Laboratories Inc. (BIO) to pursue more compelling opportunities [12] Economic Outlook - As Q4 approaches, U.S. markets are balancing elevated valuations against emerging macroeconomic headwinds, with the Federal Reserve's rate cut providing some support [13] - Investor sentiment remains positive, driven by AI momentum, although risks related to market concentration and policy uncertainty may lead to increased volatility [14] - There is a belief that small-cap equities may outperform large caps over the next two years, with small caps trading at historically attractive levels [14]

Core Insights - ZimVie Inc. has become a privately held company following its acquisition by ARCHIMED, an investment firm focused on healthcare industries [1][2] - The acquisition involved ARCHIMED purchasing all outstanding shares of ZimVie stock at a price of $19.00 per share, leading to ZimVie's common stock being delisted from NASDAQ [2] Company Overview: ZimVie - ZimVie is a global leader in the dental implant market, developing and delivering a comprehensive range of products for dental tooth replacement and restoration [4] - The company is headquartered in Palm Beach Gardens, Florida, and aims to enhance smiles and confidence through its innovative dental solutions, including implants and digital workflows [4] Company Overview: ARCHIMED - ARCHIMED is a leading investment firm with a focus on healthcare industries, managing €8 billion across various funds [5] - The firm combines operational, medical, scientific, and financial expertise to support healthcare businesses in areas such as MedTech, Biopharma, and Diagnostics [5] - ARCHIMED is committed to impact investing and aims to help partners innovate and expand their services [5]

Core Viewpoint - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of iTeos Therapeutics, Inc. and ZimVie Inc. [1][2] Group 1: iTeos Therapeutics, Inc. - iTeos Therapeutics, Inc. is set to be acquired by Concentra Biosciences, LLC for $10.047 in cash per share, along with a non-transferable contingent value right [1] - The contingent value right includes the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the disposition of certain product candidates within six months post-closing [1] Group 2: ZimVie Inc. - ZimVie Inc. is being sold to an affiliate of ARCHIMED for $19.00 in cash per share [2] Group 3: Legal Actions and Shareholder Rights - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4]

Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on life sciences and providing a comprehensive portfolio of products for dental tooth replacement and restoration procedures [2] - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide [2] - ZimVie aims to enhance smiles, function, and confidence through its offerings, which include dental implants, biomaterials, and digital workflow solutions [2] Upcoming Events - ZimVie management will participate in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025, at 3:00 p.m. Eastern Time [1] - A live webcast and archived recording of the event will be available on ZimVie's investor website [1]

ZimVie Inc. (NASDAQ:ZIMV) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Vafa Jamali - President & Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Kevin Caliendo - UBS William McMahon - Barclays Operator Good afternoon and welcome to ZimVie's Fourth Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode. We'll be facili ...

Core Insights - ZimVie Inc. reported a transformational year in 2024, becoming a pure play dental company and reducing net debt by over $290 million [2] - The company achieved an increase in Adjusted EBITDA margins by over 4 percentage points in Q4 2024 compared to Q4 2023, despite a softer end market [2] - ZimVie is optimistic about the long-term growth drivers in the dental implant market, supported by successful training and education programs [2] Financial Performance - Q4 2024 - Third-party net sales for Q4 2024 were $111.5 million, a decrease of 1.4% on a reported basis and 0.9% in constant currency compared to Q4 2023 [3] - The net loss for Q4 2024 was $(9.7) million, an improvement of $12.5 million from a net loss of $(22.2) million in Q4 2023 [4] - Adjusted net income for Q4 2024 was $7.6 million, an increase of $5.0 million from Q4 2023 [4] Financial Performance - Full Year 2024 - Total third-party net sales for the full year 2024 were $449.7 million, a decrease of 1.6% on a reported basis and 1.2% in constant currency compared to 2023 [6] - The net loss for the full year 2024 was $(33.8) million, an improvement of $22.2 million from a net loss of $(56.0) million in 2023 [7] - Adjusted EBITDA for the full year 2024 was $60.0 million, or 13.3% of third-party net sales, an increase of $9.2 million from 2023 [8] Financial Guidance for 2025 - Projected net sales for FY2025 are expected to be between $445 million and $460 million, reflecting a growth of (1%) to 2% [11] - Adjusted EBITDA for FY2025 is projected to be between $65 million and $70 million, indicating an increase of 8% to 17% [11] - Adjusted EPS for FY2025 is expected to be between $0.80 and $0.95, representing a growth of 29% to 53% [11] Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on developing and delivering products for dental tooth replacement and restoration procedures [13] - The company aims to improve smiles and confidence through its comprehensive portfolio, including dental implants and digital workflow solutions [13]